Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.
- DOI
- 10.1016/j.ejca.2026.116867
- Published
- 2026 Jul 26
- Container
- European journal of cancer (Oxford, England : 1990)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2026.116867,
title = {Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.},
author = {Tagliamento M and Bruzzone M and Blondeaux E and Dall'Olio F and Aldea M and Genova C and Marinello A and Remon J and Hendriks LEL and Del Mastro L and Planchard D and Barlesi F and Lambertini M and Besse B},
year = {2026},
journal = {European journal of cancer (Oxford, England : 1990)},
doi = {10.1016/j.ejca.2026.116867},
url = {https://doi.org/10.1016/j.ejca.2026.116867}
}RIS
TY - JOUR TI - Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX. AU - Tagliamento M AU - Bruzzone M AU - Blondeaux E AU - Dall'Olio F AU - Aldea M AU - Genova C AU - Marinello A AU - Remon J AU - Hendriks LEL AU - Del Mastro L AU - Planchard D AU - Barlesi F AU - Lambertini M AU - Besse B PY - 2026 JO - European journal of cancer (Oxford, England : 1990) DO - 10.1016/j.ejca.2026.116867 UR - https://doi.org/10.1016/j.ejca.2026.116867 ER -
APA
M, T., M, B., E, B., F, D., M, A., C, G., A, M., J, R., LEL, H., L, D. M., D, P., F, B., M, L., & B, B. (2026). Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2026.116867
Source records
- pubmed · retrieved 2026-09-26T08:28:25.616Z